Does Protein Restriction Inhibit Prostrate Cancer Growth

Prostate Cancer Clinical Trial

Official title:

Does Protein Restriction Inhibit Prostrate Cancer Growth

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01692587
• Other study ID #: 201011804
• Status: Completed
• Phase: N/A
• Start date: January 2011
• Est. completion date: March 2015

Study information

• Verified date: March 2021
• Source: Washington University School of Medicine
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The Purpose of the Protein Study is to investigate whether a reduced protein diet can inhibit the growth of prostate cancer in humans.

The Investigators hypothesis is that a reduced protein diet will inhibit expression of genes that are involved in the growth of prostate cancer.

Description:

The primary objective of this study is to determine whether or not a low protein diet has an inhibitory effect on prostate cancer cell growth.

The primary outcome measures relative to the investigators primary objectives are:

For Group 1 the expression of genes and proteins of the PI-3K/Akt/mTOR pathway. For Group 2 the PSA values obtained every three months.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 65
• Est. completion date: March 2015
• Est. primary completion date: March 2015
• Accepts healthy volunteers: No
• Gender: Male
• Age group: N/A and older

Eligibility

Inclusion Criteria:

group 1

1. Patient must have a diagnosis of prostate cancer confirmed by pathology.

2. Patient must be scheduled to undergo radical prostatectomy no sooner than 6 weeks from date of enrollment (to allow for a minimum of 4 weeks on the low protein diet).

3. Patient must have adequate baseline protein intake (screening 4-day food record shows protein > 1.0 g/kg FFM)

4. Patient must be able to understand the English-language instructions.

5. Patient must be able to comply with the low protein diet (as evaluated by the dietitian and other study team members).

6. Patient must be able to understand and willing to sign an IRB-approved written informed consent document.

5.2.2 Inclusion Criteria - Group 2

1. Patient must have a diagnosis of prostate cancer.

2. Patient must have previously undergone a radical prostatectomy for treatment of prostate cancer.

3. Patient must have a detectable PSA (defined as PSA = 0.1) in at least two consecutive measurements, taken at least one month apart, with no therapy between the PSA measurements. If the patient has had additional therapy after the radical prostatectomy, there must be evidence of a rising PSA (i.e., two consecutive measurements at least one month apart) after the patient has completed the intervening therapy (meaning that the patient must have failed treatment).

4. Patient must have adequate baseline protein intake (screening 4-day food record shows protein > 1.0 g/kg FFM).

5. Patient must have adequate baseline caloric intake (screening 4-day food record shows caloric intake of > 1500 kcal/day).

6. Patient must be able to understand the English-language instructions.

7. Patient must be able to comply with the low protein diet (as evaluated by the dietitian and other study team members).

8. Patient must be able to understand and willing to sign an IRB-approved written informed consent document.

Exclusion Criteria:

1. Patient must not currently be receiving any therapy for prostate cancer.

2. Patient must not have any serious chronic illness such as unstable angina, any uncontrolled metabolic disorder, or any immunologic disorder.

3. Patient must not have a history of any previous malignancy (with the exception of squamous or basal cell carcinoma of the skin) in the 5 years prior to enrollment (for Group 1) or 12 months prior to enrollment (for Group 2).

4. Patient must not have a previous history of a stroke.

5. Patient must not be taking any medications that might confound the study results (anabolic agents (such as androgen, androgen precursor, rhGH) in the 6 months prior to enrollment; corticosteroids (other than nasal) in the 6 months prior to enrollment; or finasteride or dutasteride).

6. Patient must not have dementia or any other cognitive impairment.

7. Patient must not have a lifestyle or fixed diet pattern that would interfere with participation in or interpretation of the results of this study

-

Related Conditions & MeSH terms

• Prostate Cancer
• Prostatic Neoplasms

Intervention

Other:
• Protein restrictive diet
To begin a reduced protein diet

Locations

Country	Name	City	State
United States	Washington University School of Medicine	Saint Louis	Missouri

Sponsors (1)

Lead Sponsor	Collaborator
Washington University School of Medicine

Country where clinical trial is conducted

United States, 

References & Publications (3)

Eitan E, Tosti V, Suire CN, Cava E, Berkowitz S, Bertozzi B, Raefsky SM, Veronese N, Spangler R, Spelta F, Mustapic M, Kapogiannis D, Mattson MP, Fontana L. In a randomized trial in prostate cancer patients, dietary protein restriction modifies markers of leptin and insulin signaling in plasma extracellular vesicles. Aging Cell. 2017 Dec;16(6):1430-1433. doi: 10.1111/acel.12657. Epub 2017 Sep 17. — View Citation

Fontana L, Cummings NE, Arriola Apelo SI, Neuman JC, Kasza I, Schmidt BA, Cava E, Spelta F, Tosti V, Syed FA, Baar EL, Veronese N, Cottrell SE, Fenske RJ, Bertozzi B, Brar HK, Pietka T, Bullock AD, Figenshau RS, Andriole GL, Merrins MJ, Alexander CM, Kimple ME, Lamming DW. Decreased Consumption of Branched-Chain Amino Acids Improves Metabolic Health. Cell Rep. 2016 Jul 12;16(2):520-530. doi: 10.1016/j.celrep.2016.05.092. Epub 2016 Jun 23. — View Citation

Treviño-Villarreal JH, Reynolds JS, Bartelt A, Langston PK, MacArthur MR, Arduini A, Tosti V, Veronese N, Bertozzi B, Brace LE, Mejia P, Trocha K, Kajitani GS, Longchamp A, Harputlugil E, Gathungu R, Bird SS, Bullock AD, Figenshau RS, Andriole GL, Thompson A, Heeren J, Ozaki CK, Kristal BS, Fontana L, Mitchell JR. Dietary protein restriction reduces circulating VLDL triglyceride levels via CREBH-APOA5-dependent and -independent mechanisms. JCI Insight. 2018 Nov 2;3(21). pii: 99470. doi: 10.1172/jci.insight.99470. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Group1--Expression of genes and proteins of the PI-3K/Akt/mTOR pathway. Group 2--PSA values obtained every three months	The investigators will be looking at the increase or decrease of PSA values between control and protein restricted diet participants obtained for the length of study.	group 1- (4-6 weeks), group 2 -(52 weeks)